Kodiak Sciences (KOD) Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kodiak Sciences in the last twelve months. There are currently 1 sell rating and 6 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" KOD shares.
View KOD analyst ratings or view top-rated stocks.

7 Wall Street research analysts have issued 1-year price targets for Kodiak Sciences' shares. Their KOD share price forecasts range from $4.00 to $10.00. On average, they anticipate the company's stock price to reach $7.33 in the next year. This suggests a possible upside of 276.1% from the stock's current price.
View analysts price targets for KOD or view top-rated stocks among Wall Street analysts.

Kodiak Sciences' stock was trading at $7.16 at the beginning of 2023. Since then, KOD stock has decreased by 72.8% and is now trading at $1.95.
View the best growth stocks for 2023 here.

Kodiak Sciences saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 2,710,000 shares, an increase of 14.3% from the August 15th total of 2,370,000 shares. Based on an average daily trading volume, of 1,160,000 shares, the days-to-cover ratio is currently 2.3 days. Currently, 5.5% of the company's shares are sold short.
View Kodiak Sciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our KOD earnings forecast.

Kodiak Sciences Inc. (NASDAQ:KOD) released its quarterly earnings results on Monday, August, 14th. The company reported ($1.53) EPS for the quarter, missing the consensus estimate of ($1.23) by $0.30.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kodiak Sciences investors own include Quest Diagnostics (DGX), Cronos Group (CRON), Deere & Company (DE), GrowGeneration (GRWG), Immunomedics (IMMU), Teck Resources (TECK), Abbott Laboratories (ABT), Ability (ABIL), AbbVie (ABBV) and

(KOD) raised $126 million in an initial public offering on Thursday, October 4th 2018. The company issued 9,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Barclays and Chardan were co-managers.

Kodiak Sciences trades on the NASDAQ under the ticker symbol "KOD."

Kodiak Sciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.61%), Dimensional Fund Advisors LP (1.38%), Geode Capital Management LLC (1.28%), State Street Corp (1.21%), Goldman Sachs Group Inc. (0.97%) and Acadian Asset Management LLC (0.88%). Insiders that own company stock include Bros Advisors Lp Baker, Jason Ehrlich, John A Borgeson and Victor Perlroth.
View institutional ownership trends.

Shares of KOD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KOD stock can currently be purchased for approximately $1.95.

Kodiak Sciences (NASDAQ:KOD) has a market capitalization of $102.28 million. The company earns $-333,820,000.00 in net income (profit) each year or ($5.70) on an earnings per share basis.

The company employs 118 workers across the globe.

Kodiak Sciences' mailing address is 2631 HANOVER STREET, PALO ALTO CA, 94304. The official website for the company is kodiak.com. The company can be reached via phone at (650) 281-0850 or via email at ir@kodiak.com.